HB1191 Engrossed

1 AN ACT concerning insurance.

2 Be it enacted by the People of the State of Illinois, 3 represented in the General Assembly:

4 Section 5. The Illinois Insurance Code is amended by 5 changing Sections 356z.16 and 364.01 as follows:

6 (215 ILCS 5/356z.16)

7 Sec. 356z.16. Applicability of mandated benefits to 8 supplemental policies. Unless specified otherwise, the 9 following Sections of the Illinois Insurance Code do not apply to short-term travel, disability income, long-term care, 10 accident only, or limited or specified disease policies: 356b, 11 356c, 356d, 356g, 356k, 356m, 356n, 356p, 356q, 356r, 356t, 12 356u, 356w, 356x, 356z.1, 356z.2, 356z.4, 356z.5, 356z.6, 13 14 356z.8, 356z.12, 364.01, 367.2-5, and 367e.

15 (Source: P.A. 96-180, eff. 1-1-10; 96-1000, eff. 7-2-10; 16 96-1034, eff. 1-1-11.)

17 (215 ILCS 5/364.01)

18

Sec. 364.01. Qualified clinical cancer trials.

(a) No individual or group policy of accident and health insurance issued or renewed in this State may be cancelled or non-renewed for any individual based on that individual's participation in a qualified clinical <u>cancer</u> trial.

HB1191 Engrossed - 2 - LRB097 06572 RPM 46657 b Qualified clinical cancer trials must meet the 1 (b) 2 following criteria: (1) the effectiveness of the treatment has not been 3 determined relative to established therapies; 4 5 (2) the trial is under clinical investigation as part 6 of an approved cancer research trial in Phase II, Phase III, or Phase IV of investigation; 7 8 (3) the trial is: 9 (A) approved by the Food and Drug Administration; 10 or 11 (B) approved and funded by the National Institutes 12 Health, the Centers for Disease Control of and 13 Prevention, the Agency for Healthcare Research and 14 Quality, the United States Department of Defense, the 15 United States Department of Veterans Affairs, or the 16 United States Department of Energy in the form of an 17 investigational new drug application, or a cooperative group or center of any entity described in this 18 19 subdivision (B); and (4) the patient's primary care physician, if any, is 20 involved in the coordination of care. 21 22 (c) No group policy of accident and health insurance shall 23 exclude coverage for any routine patient care administered to 24 an insured who is a qualified individual participating in a 25 qualified clinical cancer trial, if the policy covers that same

26 routine patient care of insureds not enrolled in a qualified

HB1191 Engrossed - 3 - LRB097 06572 RPM 46657 b

1 <u>clinical cancer trial.</u>

2	(d) The coverage that may not be excluded under subsection
3	(c) of this Section is subject to all terms, conditions,
4	restrictions, exclusions, and limitations that apply to the
5	same routine patient care received by an insured not enrolled
6	in a qualified clinical cancer trial, including the application
7	of any authorization requirement, utilization review, or
8	medical management practices. The insured or enrollee shall
9	incur no greater out-of-pocket liability than had the insured
10	or enrollee not enrolled in a qualified clinical cancer trial.
11	(e) If the group policy of accident and health insurance
12	uses a preferred provider program and a preferred provider
13	provides routine patient care in connection with a qualified
14	clinical cancer trial, then the insurer may require the insured
15	to use the preferred provider if the preferred provider agrees
16	to provide to the insured that routine patient care.
17	(f) A qualified clinical cancer trial may not pay or refuse
18	to pay for routine patient care of an individual participating
19	in the trial, based in whole or in part on the person's having
20	or not having coverage for routine patient care under a group
21	policy of accident and health insurance.
22	(g) Nothing in this Section shall be construed to limit an
23	insurer's coverage with respect to clinical trials.
24	(h) Nothing in this Section shall require coverage for
25	out-of-network services where the underlying health benefit
26	plan does not provide coverage for out-of-network services.

HB1191 Engrossed - 4 - LRB097 06572 RPM 46657 b

1	(i) As used in this Section, "routine patient care" means
2	all health care services provided in the qualified clinical
3	cancer trial that are otherwise generally covered under the
4	policy if those items or services were not provided in
5	connection with a qualified clinical cancer trial consistent
6	with the standard of care for the treatment of cancer,
7	including the type and frequency of any diagnostic modality,
8	that a provider typically provides to a cancer patient who is
9	not enrolled in a qualified clinical cancer trial. "Routine
10	patient care" does not include, and a group policy of accident
11	and health insurance may exclude, coverage for:
12	(1) a health care service, item, or drug that is the
13	subject of the cancer clinical trial;
14	(2) a health care service, item, or drug provided
14 15	(2) a health care service, item, or drug provided solely to satisfy data collection and analysis needs for
15	solely to satisfy data collection and analysis needs for
15 16	solely to satisfy data collection and analysis needs for the qualified clinical cancer trial that is not used in the
15 16 17	solely to satisfy data collection and analysis needs for the qualified clinical cancer trial that is not used in the direct clinical management of the patient;
15 16 17 18	solely to satisfy data collection and analysis needs for the qualified clinical cancer trial that is not used in the direct clinical management of the patient; (3) an investigational drug or device that has not been
15 16 17 18 19	solely to satisfy data collection and analysis needs for the qualified clinical cancer trial that is not used in the direct clinical management of the patient; (3) an investigational drug or device that has not been approved for market by the United States Food and Drug
15 16 17 18 19 20	solely to satisfy data collection and analysis needs for the qualified clinical cancer trial that is not used in the direct clinical management of the patient; (3) an investigational drug or device that has not been approved for market by the United States Food and Drug Administration;
15 16 17 18 19 20 21	<pre>solely to satisfy data collection and analysis needs for the qualified clinical cancer trial that is not used in the direct clinical management of the patient; (3) an investigational drug or device that has not been approved for market by the United States Food and Drug Administration; (4) transportation, lodging, food, or other expenses</pre>
15 16 17 18 19 20 21 22	<pre>solely to satisfy data collection and analysis needs for the qualified clinical cancer trial that is not used in the direct clinical management of the patient; (3) an investigational drug or device that has not been approved for market by the United States Food and Drug Administration; (4) transportation, lodging, food, or other expenses for the patient or a family member or companion of the</pre>
15 16 17 18 19 20 21 22 23	<pre>solely to satisfy data collection and analysis needs for the qualified clinical cancer trial that is not used in the direct clinical management of the patient; (3) an investigational drug or device that has not been approved for market by the United States Food and Drug Administration; (4) transportation, lodging, food, or other expenses for the patient or a family member or companion of the patient that are associated with the travel to or from a</pre>

1	trial;
2	(5) a health care service, item, or drug customarily
3	provided by the qualified clinical cancer trial sponsors
4	free of charge for any patient;
5	(6) a health care service or item, which except for the
6	fact that it is being provided in a qualified clinical
7	cancer trial, is otherwise specifically excluded from
8	coverage under the insured's policy, including:
9	(A) costs of extra treatments, services,
10	procedures, tests, or drugs that would not be performed
11	or administered except for the fact that the insured is
12	participating in the cancer clinical trial; and
13	(B) costs of nonhealth care services that the
14	patient is required to receive as a result of
15	participation in the approved cancer clinical trial;
16	(7) costs for services, items, or drugs that are
17	eligible for reimbursement from a source other than a
18	patient's contract or policy providing for third-party
19	payment or prepayment of health or medical expenses,
20	including the sponsor of the approved cancer clinical
21	trial; or
22	(8) costs associated with approved cancer clinical
23	trials designed exclusively to test toxicity or disease
24	pathophysiology, unless the policy covers these expenses
25	for a cancer patient who is not enrolled in a qualified
26	clinical cancer trial; or

HB1191 Engrossed - 6 - LRB097 06572 RPM 46657 b

1	(9) a health care service or item that is eligible for
2	reimbursement by a source other than the insured's policy,
3	including the sponsor of the qualified clinical cancer
4	trial.
5	The definitions of the terms "health care services",
6	"Non-Preferred Provider", "Preferred Provider", and "Preferred
7	Provider Program", stated in 50 IL Adm. Code Part 2051
8	Preferred Provider Programs apply to these terms in this
9	Section.
10	(j) The external review procedures established under the
11	Health Carrier External Review Act shall apply to the
12	provisions under this Section.
13	(Source: P.A. 93-1000, eff. 1-1-05.)

Section 99. Effective date. This Act takes effect January 15 1, 2012.